Citius Pharmaceuticals, Inc.
CTXR
$0.85
$0.000.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.43M | -40.26M | -42.05M | -39.68M | -39.14M |
| Total Depreciation and Amortization | 214.20K | 205.90K | 217.30K | 213.40K | 209.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.61M | 9.72M | 10.46M | 11.41M | 12.41M |
| Change in Net Operating Assets | 1.05M | 9.76M | 7.82M | 1.26M | -1.69M |
| Cash from Operations | -26.55M | -20.58M | -23.55M | -26.79M | -28.20M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.75M | -5.00M | -5.00M | -5.00M | -5.00M |
| Cash from Investing | -5.75M | -5.00M | -5.00M | -5.00M | -5.00M |
| Total Debt Issued | 1.30M | 1.30M | -- | -- | -- |
| Total Debt Repaid | -300.00K | -300.00K | -- | -- | -- |
| Issuance of Common Stock | 32.30M | 16.59M | 19.84M | 16.38M | 13.80M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 200.00 | 100.00 | -- | -- | -- |
| Repurchase of Preferred Stock | -200.00 | -100.00 | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -3.83M | -3.83M | -3.83M | -3.83M |
| Cash from Financing | 33.30M | 13.76M | 16.01M | 12.55M | 9.97M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.00M | -11.82M | -12.53M | -19.25M | -23.23M |